This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.0 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>98% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Human PD-L1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.
The purity of Human PD-L1, His Tag (Cat. No. PD1-H5229) was more than 90% and the molecular weight of this protein is around 30-50 kDa verified by SEC-MALS.
Immobilized Human PD-L1, His Tag (Cat. No. PD1-H5229) at 1 μg/mL (100 μL/well) can bind Anti-Human PD-L1 MAb (Human IgG1) with a linear range of 0.1-3 ng/mL (QC tested).
Immobilized Human PD-L1, His Tag (Cat. No. PD1-H5229) at series of concentration on MonoRabᵀᴹ Anti-His Tag (C-term) Antibody precoated (0.1 μg/well) plate, can bind Human PD-1, Mouse IgG2a Fc Tag (HPLC-verified) (Cat. No. PD1-H5255) at 5 μg/mL (100 μL/well) with a linear range of 10-78 ng/mL (Routinely tested).
Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) at 1 μg/mL (5 μL/well) can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with a linear range of 0.02-0.625 μg/mL as determined in a alphaLISA homogeneous assay (Routinely tested).
Human PD-1, Fc Tag (Cat. No. PD1-H5257) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 3.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Anti-Human PD-L1 Mab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 0.286 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Loaded Human PD-1, Fc Tag, low endotoxin (Cat. No. PD1-H5257) on ProteinA Biosensor, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 5.3 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
Loaded Anti-Human PD-L1 MAb (Human IgG1) on AHC Biosensor, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 1.61 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Authors: Zhai T, Wang C, Xu Y, et al.
Journal: J Immunother Cancer 2021
Application: Cell based blocking assay
Heterocyclic compounds as immunomodulators
Authors: L Wu, J Li, W Yao
Journal: US10669271B2 2020
Application: Binding Assay
Authors: Wang Y, Ni H, Zhou S, et al.
Journal: Cancer Immunol Immunother 2020
Application: BLI
Heterocyclic compounds as immunomodulators
Authors: L Wu, F Zhang, S Mei, et al.
Journal: US10669271B2 2020
Application: Binding Assay
Authors: Lu Y, et al
Journal: Nat Med 2020
Application: Flow cytometry
Authors: X Qian, et al
Journal: US20190330348A1 2019
Application: ELISA
Authors: SGT Devaraj, et al
Journal: US20190233824A1 2019
Application: ELISA
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
Authors: Fromm G, et al
Journal: J ImmunoTher Cancer 2018
Application: SPR
Immunomodulator compounds and methods of use
Authors: P Liu, et al.
Journal: US20180177870A1 2018
Application: Alphascreen & HTRF assay
Heterocyclic compounds as immunomodulators
Authors: Zhenwu Li, et al.
Journal: US20170320875A1 2017
Application: HTRF Binding Assay
Hererocyclic compounds as immunomodulators
Authors: J Li, et al.
Journal: US20170145025A1 2017
Application: HTRF Binding Assay
Hererocyclic compounds as immunomodulators
Authors: L Wu, et al.
Journal: US20170107216A1 2017
Application: HTRF Binding Assay
A novel PD-L1-targeting antagonistic DNA aptamer with antitumor effects.
Authors: Lai WY, et al.
Journal: Mol Ther Nucleic Acids 2016
Application: ELISA-based competition assay
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $330.00
Price(USD) : $2200.00
ACROBiosystems has developed a series of critical reagents for COVID-19 vaccine development and evaluation,including proteins, antibodies and kits. These featured products are suitable for IgG/M antibody titer detection, neutralizing antibody titer detection and antigen titer detection.
High quality SARS-CoV-2 S protein, S1 protein and human ACE2 protein based on the human cell expression platform of HEK293.
ACROBiosystems has developed a serial of high-quality antigen and antibody reagents, including super stable trimeric S protein, S RBD, S1, S2, N proteins mainly expressed by HEK 293 and paired antibodies with outstanding sensitivity verified by inactivated virus samples.
ACROBiosystems has developed a series of kit products using its high-quality SARS-CoV-2 antigen proteins to improve the efficiency of anti-SARS-CoV-2 drugs and vaccines development.
This web search service is supported by Google Inc.
A-Z